The resistance tetrad: Amino acid hotspots for kinome-wide exploitation of drug-resistant protein kinase alleles

Methods in Enzymology

Volumn 548, Issue C, 2014, Pages 117-146

  Bailey, Fiona P ^a   Andreev, Veselin I ^b   Eyers, Patrick A ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b NONE

Author keywords

ATP; Cancer; Drug; Gatekeeper; Hinge; Inhibitor; Kinase; Kinome; Ligand; Mutation; Polypharmacology; Resistance

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; AMINO ACID; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; TETRACYCLINE; RECOMBINANT PROTEIN;

ALLELE; ARTICLE; BINDING AFFINITY; BIOCHEMISTRY; BIOINFORMATICS; CATALYSIS; CELL GROWTH ASSAY; CELL SELECTION; CHEMICAL GENETICS; COLONY FORMATION; DRUG BINDING SITE; DRUG MECHANISM; DRUG RESISTANCE; DRUG SCREENING; DRUG SPECIFICITY; DRUG STRUCTURE; ENZYME ACTIVE SITE; GENETIC TRANSFECTION; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; IN VITRO STUDY; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; ANIMAL; BIOCATALYSIS; CHEMICAL PHENOMENA; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; DRUG EFFECTS; ENZYME SPECIFICITY; GENETICS; METABOLISM; MUTATION; PROCEDURES; PROTEIN CONFORMATION; PROTEOMICS; SURFACE PROPERTY;

PYRONIA TITHONUS;

ALLELES; ANIMALS; BIOCATALYSIS; CATALYTIC DOMAIN; DRUG DESIGN; DRUG RESISTANCE; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MODELS, MOLECULAR; MUTATION; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEOMICS; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY; SURFACE PROPERTIES;

EID: 84925427918     PISSN: 00766879     EISSN: 15577988     Source Type: Book Series    
DOI: 10.1016/B978-0-12-397918-6.00005-7     Document Type: Chapter

References (111)

1. I. Aliagas-Martin, D. Burdick, L. Corson, J. Dotson, J. Drummond, and C. Fields A class of 2,4-bisanilinopyrimidine aurora A inhibitors with unusually high selectivity against aurora B Journal of Medicinal Chemistry 52 2009 3300 3307
2. T. Anastassiadis, S.W. Deacon, K. Devarajan, H. Ma, and J.R. Peterson Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity Nature Biotechnology 29 2011 1039 1045
3. M.M. Awad, J.A. Engelman, and A.T. Shaw Acquired resistance to crizotinib from a mutation in CD74-ROS1 The New England Journal of Medicine 369 2013 1173
4. M. Azam An in vitro screening to identify drug-resistant mutations for target-directed chemotherapeutic agents Methods in Molecular Biology 928 2012 175 184
5. M. Azam, R.R. Latek, and G.Q. Daley Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL Cell 112 2003 831 843
6. M. Azam, M.A. Seeliger, N.S. Gray, J. Kuriyan, and G.Q. Daley Activation of tyrosine kinases by mutation of the gatekeeper threonine Nature Structural and Molecular Biology 15 2008 1109 1118
7. J. Bain, H. Mclauchlan, M. Elliott, and P. Cohen The specificities of protein kinase inhibitors: An update The Biochemical Journal 371 2003 199 204
8. J. Bain, L. Plater, M. Elliott, N. Shpiro, C.J. Hastie, and H. Mclauchlan The selectivity of protein kinase inhibitors: A further update The Biochemical Journal 408 2007 297 315
9. A. Balla, G. Tuymetova, B. Toth, Z. Szentpetery, X. Zhao, and Z.A. Knight Design of drug-resistant alleles of type-III phosphatidylinositol 4-kinases using mutagenesis and molecular modeling Biochemistry 47 2008 1599 1607
10. D. Balzano, S. Santaguida, A. Musacchio, and F. Villa A general framework for inhibitor resistance in protein kinases Chemistry and Biology 18 2011 966 975
11. P. Bamborough, D. Drewry, G. Harper, G.K. Smith, and K. Schneider Assessment of chemical coverage of kinome space and its implications for kinase drug discovery Journal of Medicinal Chemistry 51 2008 7898 7914
12. M. Bantscheff, D. Eberhard, Y. Abraham, S. Bastuck, M. Boesche, and S. Hobson Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors Nature Biotechnology 25 2007 1035 1044
13. R. Barouch-Bentov, and K. Sauer Mechanisms of drug resistance in kinases Expert Opinion on Investigational Drugs 20 2011 153 208
14. J.A. Bikker, N. Brooijmans, A. Wissner, and T.S. Mansour Kinase domain mutations in cancer: Implications for small molecule drug design strategies Journal of Medicinal Chemistry 52 2009 1493 1509
15. A.C. Bishop, J.A. Ubersax, D.T. Petsch, D.P. Matheos, N.S. Gray, and J. Blethrow A chemical switch for inhibitor-sensitive alleles of any protein kinase Nature 407 2000 395 401
16. S. Blencke, B. Zech, O. Engkvist, Z. Greff, L. Orfi, and Z. Horvath Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors Chemistry and Biology 11 2004 691 701
17. H.A. Bradeen, C.A. Eide, T. O'Hare, K.J. Johnson, S.G. Willis, and F.Y. Lee Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: High efficacy of drug combinations Blood 108 2006 2332 2338
18. M.E. Burkard, and P.V. Jallepalli Validating cancer drug targets through chemical genetics Biochimica et Biophysica Acta 1806 2010 251 257
19. M.E. Burkard, A. Santamaria, and P.V. Jallepalli Enabling and disabling polo-like kinase 1 inhibition through chemical genetics ACS Chemical Biology 7 2012 978 981
20. T.A. Carter, L.M. Wodicka, N.P. Shah, A.M. Velasco, M.A. Fabian, and D.K. Treiber Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases Proceedings of the National Academy of Sciences of the United States of America 102 2005 11011 11016
21. C. Chen, B.H. Ha, A.F. Thevenin, H.J. Lou, R. Zhang, and K.Y. Yip Identification of a major determinant for serine-threonine kinase phosphoacceptor specificity Molecular Cell 53 2014 140 147
22. H. Chen, J. Ma, W. Li, A.V. Eliseenkova, C. Xu, and T.A. Neubert A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases Molecular Cell 27 2007 717 730
23. Y. Cheng, and W.H. Prusoff Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction Biochemical Pharmacology 22 1973 3099 3108
24. K. Clark, K.F. Mackenzie, K. Petkevicius, Y. Kristariyanto, J. Zhang, and H.G. Choi Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages Proceedings of the National Academy of Sciences of the United States of America 109 2012 16986 16991
25. P. Cohen Protein kinases - The major drug targets of the twenty-first century? Nature Reviews. Drug Discovery 1 2002 309 315
26. P. Cohen Guidelines for the effective use of chemical inhibitors of protein function to understand their roles in cell regulation The Biochemical Journal 425 2010 53 54
27. P. Cohen, and D.R. Alessi Kinase drug discovery - What's next in the field? ACS Chemical Biology 8 2013 96 104
28. J. Cools, N. Mentens, P. Furet, D. Fabbro, J.J. Clark, and J.D. Griffin Prediction of resistance to small molecule FLT3 inhibitors: Implications for molecularly targeted therapy of acute leukemia Cancer Research 64 2004 6385 6389
29. M.J. Cooper, N.J. Cox, E.I. Zimmerman, B.J. Dewar, J.S. Duncan, and M.C. Whittle Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia PLoS One 8 2013 e66755
30. A. Cuenda, J. Rouse, Y.N. Doza, R. Meier, P. Cohen, and T.F. Gallagher SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1 FEBS Letters 364 1995 229 233
31. A.C. Dar, T.K. Das, K.M. Shokat, and R.L. Cagan Chemical genetic discovery of targets and anti-targets for cancer polypharmacology Nature 486 2012 80 84
32. A.C. Dar, and K.M. Shokat The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling Annual Review of Biochemistry 80 2011 769 795
33. S.P. Davies, H. Reddy, M. Caivano, and P. Cohen Specificity and mechanism of action of some commonly used protein kinase inhibitors The Biochemical Journal 351 2000 95 105
34. M.I. Davis, J.P. Hunt, S. Herrgard, P. Ciceri, L.M. Wodicka, and G. Pallares Comprehensive analysis of kinase inhibitor selectivity Nature Biotechnology 29 2011 1046 1051
35. X. Deng, N. Dzamko, A. Prescott, P. Davies, Q. Liu, and Q. Yang Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2 Nature Chemical Biology 7 2011 203 205
36. A. Deshpande, M.M. Reddy, G.O. Schade, A. Ray, T.K. Chowdary, and J.D. Griffin Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms Leukemia 26 2012 708 715
37. C.A. Dodson, M. Kosmopoulou, M.W. Richards, B. Atrash, V. Bavetsias, and J. Blagg Crystal structure of an aurora-A mutant that mimics aurora-B bound to MLN8054: Insights into selectivity and drug design The Biochemical Journal 427 2010 19 28
38. J.S. Duncan, M.C. Whittle, K. Nakamura, A.N. Abell, A.A. Midland, and J.S. Zawistowski Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer Cell 149 2012 307 321
39. A. Echalier, E. Cot, A. Camasses, E. Hodimont, F. Hoh, and P. Jay An integrated chemical biology approach provides insight into cdk2 functional redundancy and inhibitor sensitivity Chemistry and Biology 19 2012 1028 1040
40. C.M. Emery, K.G. Vijayendran, M.C. Zipser, A.M. Sawyer, L. Niu, and J.J. Kim MEK1 mutations confer resistance to MEK and B-RAF inhibition Proceedings of the National Academy of Sciences of the United States of America 106 2009 20411 20416
41. J.A. Endicott, M.E. Noble, and L.N. Johnson The structural basis for control of eukaryotic protein kinases Annual Review of Biochemistry 81 2012 587 613
42. P.A. Eyers, M.E. Churchill, and J.L. Maller The aurora A and aurora B protein kinases: A single amino acid difference controls intrinsic activity and activation by TPX2 Cell Cycle 4 2005 784 789
43. P.A. Eyers, M. Craxton, N. Morrice, P. Cohen, and M. Goedert Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution Chemistry and Biology 5 1998 321 328
44. P.A. Eyers, I.P. Van Den, R.A. Quinlan, M. Goedert, and P. Cohen Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580 FEBS Letters 451 1999 191 196
45. M.A. Fabian, W.H. Biggs 3rd., D.K. Treiber, C.E. Atteridge, M.D. Azimioara, and M.G. Benedetti A small molecule-kinase interaction map for clinical kinase inhibitors Nature Biotechnology 23 2005 329 336
46. O. Fedorov, B. Marsden, V. Pogacic, P. Rellos, S. Muller, and A.N. Bullock A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases Proceedings of the National Academy of Sciences of the United States of America 104 2007 20523 20528
47. C.E. Fitzgerald, S.B. Patel, J.W. Becker, P.M. Cameron, D. Zaller, and V.B. Pikounis Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity Nature Structural Biology 10 2003 764 769
48. F. Girdler, K.E. Gascoigne, P.A. Eyers, S. Hartmuth, C. Crafter, and K.M. Foote Validating aurora B as an anti-cancer drug target Journal of Cell Science 119 2006 3664 3675
49. F. Girdler, F. Sessa, S. Patercoli, F. Villa, A. Musacchio, and S. Taylor Molecular basis of drug resistance in aurora kinases Chemistry and Biology 15 2008 552 562
50. K. Godl, J. Wissing, A. Kurtenbach, P. Habenberger, S. Blencke, and H. Gutbrod An efficient proteomics method to identify the cellular targets of protein kinase inhibitors Proceedings of the National Academy of Sciences of the United States of America 100 2003 15434 15439
51. M.E. Gorre, M. Mohammed, K. Ellwood, N. Hsu, R. Paquette, and P.N. Rao Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 2001 876 880
52. C.J. Green, O. Goransson, G.S. Kular, N.R. Leslie, A. Gray, and D.R. Alessi Use of Akt inhibitor and a drug-resistant mutant validates a critical role for protein kinase B/Akt in the insulin-dependent regulation of glucose and system a amino acid uptake The Journal of Biological Chemistry 283 2008 27653 27667
53. X. Guo, R.E. Gerl, and J.W. Schrader Defining the involvement of p38alpha MAPK in the production of anti- and proinflammatory cytokines using an SB 203580-resistant form of the kinase The Journal of Biological Chemistry 278 2003 22237 22242
54. C.A. Hall-Jackson, P.A. Eyers, P. Cohen, M. Goedert, F.T. Boyle, and N. Hewitt Paradoxical activation of Raf by a novel Raf inhibitor Chemistry and Biology 6 1999 559 568
55. C.A. Hall-Jackson, M. Goedert, P. Hedge, and P. Cohen Effect of SB 203580 on the activity of c-Raf in vitro and in vivo Oncogene 18 1999 2047 2054
56. J.H. Hanke, J.P. Gardner, R.L. Dow, P.S. Changelian, W.H. Brissette, and E.J. Weringer Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation The Journal of Biological Chemistry 271 1996 695 701
57. S.K. Hanks, and T. Hunter Protein kinases 6. The eukaryotic protein kinase superfamily: Kinase (catalytic) domain structure and classification FASEB Journal 9 1995 576 596
58. T.A. Haystead The purinome, a complex mix of drug and toxicity targets Current Topics in Medicinal Chemistry 6 2006 1117 1127
59. N. Hegarat, E. Smith, G. Nayak, S. Takeda, P.A. Eyers, and H. Hochegger Aurora a and aurora B jointly coordinate chromosome segregation and anaphase microtubule dynamics Journal of Cell Biology 195 2011 1103 1113
60. J.M. Heuckmann, M. Holzel, M.L. Sos, S. Heynck, H. Balke-Want, and M. Koker ALK mutations conferring differential resistance to structurally diverse ALK inhibitors Clinical Cancer Research 17 2011 7394 7401
61. D. Huang, T. Zhou, K. Lafleur, C. Nevado, and A. Caflisch Kinase selectivity potential for inhibitors targeting the ATP binding site: A network analysis Bioinformatics 26 2010 198 204
62. M. Jemaa, I. Vitale, O. Kepp, F. Berardinelli, L. Galluzzi, and L. Senovilla Selective killing of p53-deficient cancer cells by SP600125 EMBO Molecular Medicine 4 2012 500 514
63. R. Katayama, T.M. Khan, C. Benes, E. Lifshits, H. Ebi, and V.M. Rivera Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK Proceedings of the National Academy of Sciences of the United States of America 108 2011 7535 7540
64. Z.A. Knight, H. Lin, and K.M. Shokat Targeting the cancer kinome through polypharmacology Nature Reviews. Cancer 10 2010 130 137
65. Z.A. Knight, and K.M. Shokat Features of selective kinase inhibitors Chemistry and Biology 12 2005 621 637
66. M. Kothe, D. Kohls, S. Low, R. Coli, G.R. Rennie, and F. Feru Selectivity-determining residues in Plk1 Chemical Biology and Drug Design 70 2007 540 546
67. P. Kovarik, D. Stoiber, P.A. Eyers, R. Menghini, A. Neininger, and M. Gaestel Stress-induced phosphorylation of STAT1 at Ser727 requires p38 mitogen-activated protein kinase whereas IFN-gamma uses a different signaling pathway Proceedings of the National Academy of Sciences of the United States of America 96 1999 13956 13961
68. R. Krishnamurty, and D.J. Maly Biochemical mechanisms of resistance to small-molecule protein kinase inhibitors ACS Chemical Biology 5 2010 121 138
69. N. Kwiatkowski, N. Jelluma, P. Filippakopoulos, M. Soundararajan, M.S. Manak, and M. Kwon Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function Nature Chemical Biology 6 2010 359 368
70. X. Lin, X.P. Huang, G. Chen, R. Whaley, S. Peng, and Y. Wang Life beyond kinases: Structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors Journal of Medicinal Chemistry 55 2012 5749 5759
71. P. Littlefield, M.M. Moasser, and N. Jura An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase Chemistry and Biology 21 2014 453 458
72. Y. Liu, A. Bishop, L. Witucki, B. Kraybill, E. Shimizu, and J. Tsien Structural basis for selective inhibition of Src family kinases by PP1 Chemistry and Biology 6 1999 671 678
73. Y. Liu, and N.S. Gray Rational design of inhibitors that bind to inactive kinase conformations Nature Chemical Biology 2 2006 358 364
74. M.S. Lopez, J.W. Choy, U. Peters, M.L. Sos, D.O. Morgan, and K.M. Shokat Staurosporine-derived inhibitors broaden the scope of analog-sensitive kinase technology Journal of the American Chemical Society 135 2013 18153 18159
75. G. Manning, D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam The protein kinase complement of the human genome Science 298 2002 1912 1934
76. M.R. Marit, M. Chohan, N. Matthew, K. Huang, D.A. Kuntz, and D.R. Rose Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor PLoS One 7 2012 e43437
77. J.V. Melo, and C. Chuah Resistance to imatinib mesylate in chronic myeloid leukaemia Cancer Letters 249 2007 121 132
78. C.V. Miduturu, X. Deng, N. Kwiatkowski, W. Yang, L. Brault, and P. Filippakopoulos High-throughput kinase profiling: A more efficient approach toward the discovery of new kinase inhibitors Chemistry and Biology 18 2011 868 879
79. R.J. Nichols, N. Dzamko, J.E. Hutti, L.C. Cantley, M. Deak, and J. Moran Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease The Biochemical Journal 424 2009 47 60
80. J.F. Ohren, H. Chen, A. Pavlovsky, C. Whitehead, E. Zhang, and P. Kuffa Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition Nature Structural and Molecular Biology 11 2004 1192 1197
81. S.J. O'Keefe, J.S. Mudgett, S. Cupo, J.N. Parsons, N.A. Chartrain, and C. Fitzgerald Chemical genetics define the roles of p38alpha and p38beta in acute and chronic inflammation The Journal of Biological Chemistry 282 2007 34663 34671
82. M.P. Patricelli, T.K. Nomanbhoy, J. Wu, H. Brown, D. Zhou, and J. Zhang In situ kinase profiling reveals functionally relevant properties of native kinases Chemistry and Biology 18 2011 699 710
83. M.P. Patricelli, A.K. Szardenings, M. Liyanage, T.K. Nomanbhoy, M. Wu, and H. Weissig Functional interrogation of the kinome using nucleotide acyl phosphates Biochemistry 46 2007 350 358
84. P.I. Poulikakos, Y. Persaud, M. Janakiraman, X. Kong, C. Ng, and G. Moriceau RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) Nature 480 2011 387 390
85. P.I. Poulikakos, C. Zhang, G. Bollag, K.M. Shokat, and N. Rosen RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Nature 464 2010 427 430
86. A. Ray, S.W. Cowan-Jacob, P.W. Manley, J. Mestan, and J.D. Griffin Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study Blood 109 2007 5011 5015
87. S. Roumiantsev, N.P. Shah, M.E. Gorre, J. Nicoll, B.B. Brasher, and C.L. Sawyers Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop Proceedings of the National Academy of Sciences of the United States of America 99 2002 10700 10705
88. T. Schindler, W. Bornmann, P. Pellicena, W.T. Miller, B. Clarkson, and J. Kuriyan Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase Science 289 2000 1938 1942
89. M. Schmidt, Y. Budirahardja, R. Klompmaker, and R.H. Medema Ablation of the spindle assembly checkpoint by a compound targeting Mps1 EMBO Reports 6 2005 866 872
90. P.J. Scutt, M.L. Chu, D.A. Sloane, M. Cherry, C.R. Bignell, and D.H. Williams Discovery and exploitation of inhibitor-resistant aurora and polo kinase mutants for the analysis of mitotic networks The Journal of Biological Chemistry 284 2009 15880 15893
91. K. Shah, Y. Liu, C. Deirmengian, and K.M. Shokat Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates Proceedings of the National Academy of Sciences of the United States of America 94 1997 3565 3570
92. N.P. Shah, J.M. Nicoll, B. Nagar, M.E. Gorre, R.L. Paquette, and J. Kuriyan Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia Cancer Cell 2 2002 117 125
93. N.P. Shah, C. Tran, F.Y. Lee, P. Chen, D. Norris, and C.L. Sawyers Overriding imatinib resistance with a novel ABL kinase inhibitor Science 305 2004 399 401
94. F.B. Sheinerman, E. Giraud, and A. Laoui High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding Journal of Molecular Biology 352 2005 1134 1156
95. B.J. Skaggs, M.E. Gorre, A. Ryvkin, M.R. Burgess, Y. Xie, and Y. Han Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants Proceedings of the National Academy of Sciences of the United States of America 103 2006 19466 19471
96. D.A. Sloane, M.Z. Trikic, M.L. Chu, M.B. Lamers, C.S. Mason, and I. Mueller Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237 ACS Chemical Biology 5 2010 563 576
97. J.S. Tokarski, J.A. Newitt, C.Y. Chang, J.D. Cheng, M. Wittekind, and S.E. Kiefer The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants Cancer Research 66 2006 5790 5797
98. R.K. Tyler, N. Shpiro, R. Marquez, and P.A. Eyers VX-680 inhibits aurora A and aurora B kinase activity in human cells Cell Cycle 6 2007 2846 2854
99. M. Vieth, J.J. Sutherland, D.H. Robertson, and R.M. Campbell Kinomics: Characterizing the therapeutically validated kinase space Drug Discovery Today 10 2005 839 846
100. S.A. Wacker, B.R. Houghtaling, O. Elemento, and T.M. Kapoor Using transcriptome sequencing to identify mechanisms of drug action and resistance Nature Chemical Biology 8 2012 235 237
101. R.A. Ward, M.J. Anderton, S. Ashton, P.A. Bethel, M. Box, and S. Butterworth Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR) Journal of Medicinal Chemistry 56 2013 7025 7048
102. S. Whittaker, R. Kirk, R. Hayward, A. Zambon, A. Viros, and N. Cantarino Gatekeeper mutations mediate resistance to BRAF-targeted therapies Science Translational Medicine 2 2010 35ra41
103. L.M. Wodicka, P. Ciceri, M.I. Davis, J.P. Hunt, M. Floyd, and S. Salerno Activation state-dependent binding of small molecule kinase inhibitors: Structural insights from biochemistry Chemistry and Biology 17 2010 1241 1249
104. P. Workman, and I. Collins Probing the probes: Fitness factors for small molecule tools Chemistry and Biology 17 2010 561 577
105. M.A. Young, N.P. Shah, L.H. Chao, M. Seeliger, Z.V. Milanov, and W.H. Biggs 3rd. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the aurora kinase inhibitor VX-680 Cancer Research 66 2006 1007 1014
106. C.H. Yun, K.E. Mengwasser, A.V. Toms, M.S. Woo, H. Greulich, and K.K. Wong The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proceedings of the National Academy of Sciences of the United States of America 105 2008 2070 2075
107. S. Zhang, F. Wang, J. Keats, X. Zhu, Y. Ning, and S.D. Wardwell Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen Chemical Biology and Drug Design 78 2011 999 1005
108. T. Zhou, L. Commodore, W.S. Huang, Y. Wang, M. Thomas, and J. Keats Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): Lessons for overcoming kinase inhibitor resistance Chemical Biology and Drug Design 77 2011 1 11
109. W. Zhou, D. Ercan, L. Chen, C.H. Yun, D. Li, and M. Capelletti Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Nature 462 2009 1070 1074
110. F. Zuccotto, E. Ardini, E. Casale, and M. Angiolini Through the "gatekeeper door": Exploiting the active kinase conformation Journal of Medicinal Chemistry 53 2010 2681 2694
111. E.R. Zunder, Z.A. Knight, B.T. Houseman, B. Apsel, and K.M. Shokat Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha Cancer Cell 14 2008 180 192